Bridging the species divide: transgenic mice humanized for type-I interferon response.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractWe have generated transgenic mice that harbor humanized type I interferon receptors (IFNARs) enabling the study of type I human interferons (Hu-IFN-Is) in mice. These "HyBNAR" (Hybrid IFNAR) mice encode transgenic variants of IFNAR1 and IFNAR2 with the human extracellular domains being fused to transmembrane and cytoplasmic segments of mouse sequence. B16F1 mouse melanoma cells harboring the HyBNAR construct specifically bound Hu-IFN-Is and were rendered sensitive to Hu-IFN-I stimulated anti-proliferation, STAT1 activation and activation of a prototypical IFN-I response gene (MX2). HyBNAR mice were crossed with a transgenic strain expressing the luciferase reporter gene under the control of the IFN-responsive MX2 promoter (MX2-Luciferase). Both the HyBNAR and HyBNAR/MX2-Luciferase mice were responsive to all Hu-IFN-Is tested, inclusive of IFNα2A, IFNβ, and a human superagonist termed YNSα8. The mice displayed dose-dependent pharmacodynamic responses to Hu-IFN-I injection, as assessed by measuring the expression of IFN-responsive genes. Our studies also demonstrated a weak activation of endogenous mouse interferon response, especially after high dose administration of Hu-IFNs. In sharp contrast to data published for humans, our pharmacodynamic readouts demonstrate a very short-lived IFN-I response in mice, which is not enhanced by sub-cutaneous (SC) injections in comparison to other administration routes. With algometric differences between humans and mice taken into account, the HyBNAR mice provides a convenient non-primate pre-clinical model to advance the study of human IFN-Is.
CitationBridging the species divide: transgenic mice humanized for type-I interferon response. 2014, 9 (1):e84259 PLoS ONE
The following license files are associated with this item:
- Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis.
- Authors: Harari D, Kuhn N, Abramovich R, Sasson K, Zozulya AL, Smith P, Schlapschy M, Aharoni R, Köster M, Eilam R, Skerra A, Schreiber G
- Issue date: 2014 Oct 17
- Validation of a HeLa Mx2/Luc reporter cell line for the quantification of human type I interferons.
- Authors: Seo YJ, Kim GH, Kwak HJ, Nam JS, Lee HJ, Suh SK, Baek KM, Sohn YW, Hong SH
- Issue date: 2009
- Species Specificity of Type III Interferon Activity and Development of a Sensitive Luciferase-Based Bioassay for Quantitation of Mouse Interferon-λ.
- Authors: Jacobs S, Wavreil F, Schepens B, Gad HH, Hartmann R, Rocha-Pereira J, Neyts J, Saelens X, Michiels T
- Issue date: 2018 Nov
- Defining the distinct, intrinsic properties of the novel type I interferon, IFNϵ.
- Authors: Stifter SA, Matthews AY, Mangan NE, Fung KY, Drew A, Tate MD, Soares da Costa TP, Hampsey D, Mayall J, Hansbro PM, Garcia Minambres A, Eid SG, Mak J, Scoble J, Lovrecz G, deWeerd NA, Hertzog PJ
- Issue date: 2018 Mar 2
- Type I Interferon Signaling Is Required for CpG-Oligodesoxynucleotide-Induced Control of <i>Leishmania major</i>, but Not for Spontaneous Cure of Subcutaneous Primary or Secondary <i>L. major</i> Infection.
- Authors: Schleicher U, Liese J, Justies N, Mischke T, Haeberlein S, Sebald H, Kalinke U, Weiss S, Bogdan C
- Issue date: 2018